ANIX - CIK 0000715446
The table below shows Anixa Biosciences Inc's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q4 2025 | Q4 2024 | Q4 2023 | Q4 2022 | Q4 2021 | Q4 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$2.61M | -$2.90M | -$2.31M | -$1.99M | -$1.20M | -$1.17M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | $1.23M | $2.70M | $129.00K | -$585.00K | $1.85M | $675.00K |
| Dividends paid | - | - | - | - | - |
Anixa Biosciences Inc reported operating cash flow of -$7.17M for fiscal year 2025. That is up 2.2% from -$7.33M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$3.38M (FY 2016) to -$7.17M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $1.69M | -$17.00K | $2.26M | $3.00K | - | $6.06M |